Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

C. Rosa Garrido



Author of

  • +

    P1.07 - Poster Session with Presenters Present (ID 459)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: SCLC/Neuroendocrine Tumors
    • Presentations: 1
    • +

      P1.07-009 - Outcomes of Patients with Relapsed Small-Cell Lung Cancer Treated with Paclitaxel plus Gemcitabine. 10 Year-Analysis (ID 6403)

      14:30 - 14:30  |  Author(s): C. Rosa Garrido

      • Abstract

      Background:
      We conducted a retrospective study to investigate the outcome and prognostic factors of patients with relapsed SCLC who receive second or third line chemotherapy with paclitaxel plus gemcitabine, a regimen that is used in our institution since a phase II trial in 2001. We reviewed the medical records of patients with SCLC who received paclitaxel plus gemcitabine in a ten-years period, since 2005 from 2015. Overall survival (OS) from the initiation of this regimen was evaluated, plus characteristics of these patients.

      Methods:
      Patients diagnosed of SCLC were selected from our lung cancer database, and compared with our Pharmacy Department database. We selected all patients with relapsed SCLC that received therapy with paclitaxel plus gemcitabine (PG) at any moment of the disease.

      Results:
      Patient characteristics The median age of the cohort was 58 years (43–81 years). There were 69 males (83.2%) and 14 females (16.8%). 72 patients (86.7%) had a previous history of smoking. ECOG PS at relapse was 0 in 3 (3.6%), 1 in 70 (84.3%), and 2 in 10 (12.1%) patients. Fifty patients (60.2%) had extensive disease at baseline diagnosis, and the remaining 33 (38.8%) had limited disease. All patients were exposed previously to etoposide and platinum. The platinum used was cisplatin in 52 patients (60.3%) and carboplatin in 30 patients (38.7%). Previous radiation at local tumor site was received by 38 patients (45.8%). Response The response was evaluated in 78 patients. The response post‑2 months of PG was complete response in 2 patients (2.5%), partial response in 29 (37.1%), stable disease in 24 (30.7%), and progressive disease in 23 patients (30.6%). Toxicity The median number of cycles of PG received was 8 (2-28) cycles. Toxicity related cessation of treatment was required in 12 patients (14.4%). The reason for stoppage was Grade 3–4 toxicities in 8 patients (9.6%) and deterioration in PS in 4 patients (4.8%) Outcomes The median PFS was 148 days (95% CI: 30–173.5 days) while the median OS was 172 days (95% CI: 60–485 days).

      Conclusion:
      Paclitaxel plus gemcitabine it is a well tolerated regimen in relapsed SCLC in the schedule we usually use (every 2 weeks). Unless this study is retrospective, we believe that this combination can be used nowadays in these patients, if there is no clinical trial available.

  • +

    P2.03a - Poster Session with Presenters Present (ID 464)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Advanced NSCLC
    • Presentations: 1
    • +

      P2.03a-047 - Clinical Trial Participation and Outcomes in Non-Small Cell Lung Cancer: Case-Control Study (ID 6405)

      14:30 - 14:30  |  Author(s): C. Rosa Garrido

      • Abstract

      Background:
      There is some evidence that patients who participate in clinical trials have improved outcomes compared with patients receiving standard chemotherapy. We look forward if the outcome for patients with stage III and IV non-small cell lung cancer treated on a clinical trial was associated with a better outcome at our institution, a tertiary centre in Spain.

      Methods:
      Patients with NSCLC treated on standard chemotherapy/TKI between 2010 and 2015 were matched with individuals who received 1st line chemotherapy or TKI in a clinical trial in a ratio 2:1. Cases were matched for age (<65 years or >65 years), stage (III or IV), histology (adenocarcinoma, squamous), EGFR status (mutated vs wild-type) and therapy received in 1st line (platinum doublet, TKI). All patients were World Health Organisation (WHO) performance status 0 or 1.

      Results:
      Patients in each group were well matched for stage, histological sub type, surgery and treatment. The median follow up for patients treated on a trial was 3.2 years, compared with 2.8 years for matched patients who received standard 1st line therapy. The median overall survival for patients treated on a trial was 19.4 months, compared with 15.8 months for those in a matched control group. The difference between groups was not significant (Log rank test, HR 0.81, 95% CI: 0.42 to 1.35, p=0.5). The difference in overall survival between groups was not significant (Log Rank test, HR 0.87, 95%CI: 0.46 to1.64, p=0.7).

      Conclusion:
      Data from our institution, a tertiary centre active in clinical trials, shows a good outcome for patients with advanced NSCLC regardless of whether they received 1st line therapy on a clinical trial. There is a trend for a better outcome for those patients that are enrolled in a clinical trial, so this encourage our active participation in clinical research.